Evidence map›Paper›PMID 27629435›Full record

ArticleHepatology (Baltimore, Md.)2016

The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.

Romina Fiorotto, Ambra Villani, Antonis Kourtidis, Roberto Scirpo, Mariangela Amenduni, Peter J Geibel, Massimiliano Cadamuro, Carlo Spirli, Panos Z Anastasiadis, Mario Strazzabosco

Open access · bronzeAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 72 citations in OpenAlex.

  1. Review
  2. Pathophysiology of cystic fibrosis-related liver disease.Current opinion in gastroenterology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Lower Expression ofCancers · 2023
    Article
  9. CFTR and Gastrointestinal Cancers: An Update.Journal of personalized medicine · 2022
    Review
  10. CFTR, Cell Junctions and the Cytoskeleton.International journal of molecular sciences · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Current Treatment Options for Cystic Fibrosis-Related Liver Disease.International journal of molecular sciences · 2020
    Review
  18. Review: Pathogenesis of cholestatic liver diseases.World journal of hepatology · 2020
    Review
  19. Cystic Fibrosis, CFTR, and Colorectal Cancer.International journal of molecular sciences · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Romina FiorottoSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Ambra VillaniSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Antonis KourtidisDepartment of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL.
Roberto ScirpoSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Mariangela AmenduniSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Peter J GeibelDepartment of Surgery, Yale University, New Haven, CT.
Massimiliano CadamuroInternational Center for Digestive Health, University of Milan-Bicocca, Milan, Italy.
Carlo SpirliSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Panos Z AnastasiadisDepartment of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL.
Mario StrazzaboscoSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Yale University · USMayo Clinic in Florida · USUniversity of Milano-Bicocca · IT

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
Liver disease in CF: CFTR controls innate immunity in biliary epitheliumR01DK096096 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2013 to 2022
$4.6M
Cross talk between epithelial, inflammatory and mesenchymal cells in the development of portal fibrosisR01DK101528 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2015 to 2023
$3.5M
Epithelial Angiogenic Signaling in Polycystic Diseases of the LiverR01DK079005 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2008 to 2017
$3.5M
Combining Anti-Invasive and Anti-Angiogenic Therapies for the treatment of GBMR01NS069753 · NINDS · MAYO CLINIC JACKSONVILLE · PI ANASTASIADIS, PANAGIOTIS Z. · 2010 to 2014
$1.6M
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS P30 DK034989NIDDK NIH HHS R01 DK079005NIDDK NIH HHS R01 DK096096NIDDK NIH HHS R01 DK101528NINDS NIH HHS R01 NS069753
6 · The paper itself

Abstract

In the liver, the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) regulates bile secretion and other functions at the apical membrane of biliary epithelial cells (i.e., cholangiocytes). CF-related liver disease is a major cause of death in patients with CF. CFTR dysfunction affects innate immune pathways, generating a para-inflammatory status in the liver and other epithelia. This study investigates the mechanisms linking CFTR to toll-like receptor 4 activity. We found that CFTR is associated with a multiprotein complex at the apical membrane of normal mouse cholangiocytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity. In CFTR-defective cholangiocytes, Src tyrosine kinase self-activates and phosphorylates toll-like receptor 4, resulting in activation of nuclear factor kappa-light-chain-enhancer of activated B cells and increased proinflammatory cytokine production in response to endotoxins. This Src/nuclear factor kappa-light-chain-enhancer of activated B cells-dependent inflammatory process attracts inflammatory cells but also generates changes in the apical junctional complex and loss of epithelial barrier function. Inhibition of Src decreased the inflammatory response of CF cholangiocytes to lipopolysaccharide, rescued the junctional defect in vitro, and significantly attenuated endotoxin-induced biliary damage and inflammation in vivo (Cftr knockout mice).

conclusionThese findings reveal a novel function of CFTR as a regulator of toll-like receptor 4 responses and cell polarity in biliary epithelial cells; this mechanism is pathogenetic, as shown by the protective effects of Src inhibition in vivo, and may be a novel therapeutic target in CF-related liver disease and other inflammatory cholangiopathies. (Hepatology 2016;64:2118-2134).

Indexed as

AnimalsBile DuctsCell MembraneCells, CulturedCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorEpitheliumInflammationMicePermeabilitysrc-Family KinasesToll-Like Receptor 4Cystic Fibrosis Transmembrane Conductance Regulatorsrc-Family KinasesToll-Like Receptor 4

Identifiers

PMID27629435
PMCPMC5115965
OpenAlexW2519579445

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.